One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Moderate Intensity Exercise Training Improves Skeletal Muscle Performance in Symptomatic and Asymptomatic Statin Users
Neeltje A.E.AllardMDaLandoJanssenMDabThorbenAussiekerMSccAnouk A.F.StoffelsMScdRichard J.RodenburgPhDeWillem J.J.AssendelftMD, PhDfPaul D.ThompsonMDgTimSnijdersPhDcMaria T.E.HopmanMD, PhDaSilvieTimmersPhDh
doi : 10.1016/j.jacc.2021.08.075
Volume 78, Issue 21, 23 November 2021, Pages 2023-2037
The combination of statin therapy and physical activity reduces cardiovascular disease risk in patients with hyperlipidemia more than either treatment alone. However, mitochondrial dysfunction associated with statin treatment could attenuate training adaptations.
Exercise Training Improves Muscle Performance and Quality of Life in Patients With Statin Muscle Symptoms?
Robert S.RosensonMDaBeth A.TaylorMDbIrwin J.KurlandMD, PhDc
doi : 10.1016/j.jacc.2021.09.023
Volume 78, Issue 21, 23 November 2021, Pages 2038-2041
Effect of ?-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction
PatriciaPalauMD, PhDa?JuliaSellerMDb?EloyDomínguezMD, PhDcClaraSastreRNaJose MaríaRamónRNaRafaelde La EspriellaMDaEnriqueSantasMD, PhDaGemaMiñanaMD, PhDadVicentBodíMD, PhDadJuanSanchisMD, PhDadAlfonsoValleMDbF. JavierChorroMD, PhDadPauLlácerMD, PhDdeAntoniBayés-GenísMD, PhDdfgJulioNúñezMD, PhDad
doi : 10.1016/j.jacc.2021.08.073
Volume 78, Issue 21, 23 November 2021, Pages 2042-2056
Chronotropic incompetence has shown to be associated with a decrease in exercise capacity in heart failure with preserved ejection fraction (HFpEF), yet ?-blockers are commonly used in HFpEF despite the lack of robust evidence.
The Link Between Heart Rate, Exercise, and ?-Blocker in HFpEF: Time to Untie the Knot?
MarcoGuazziMD, PhD
doi : 10.1016/j.jacc.2021.09.018
Volume 78, Issue 21, 23 November 2021, Pages 2057-2059
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
MarcoValgimigliMD, PhDaDavideCaoMDbDominick J.AngiolilloMD, PhDcSripalBangaloreMD, MHAdDeepak L.BhattMD, MPHeJunboGeMDfJamesHermillerMDgRaj R.MakkarMDhFranz-JosefNeumannMDiShigeruSaitoMDjHectorPiconMDkRalphToelgMDlAzizMaksoudMDmBassem M.ChehabMDnJames W.ChoiMDoGianlucaCampoMDpJose M.De la Torre HernandezMD, PhDqVijayKunadianMDrGennaroSardellaMDsHolgerThieleMDtOlivierVarenneMDuPascalVranckxMDvStephanWindeckerMDwYujieZhouMDxMitchell W.KrucoffMDyKarineRusterPhDzYanZhengMSzRoxanaMehranMDbon behalf of theXIENCE 90 and XIENCE 28 Investigators
doi : 10.1016/j.jacc.2021.08.074
Volume 78, Issue 21, 23 November 2021, Pages 2060-2072
The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown.
1 Month of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: The New Standard??
JayGiriMD, MPHAlexander C.FanaroffMD, MHS
doi : 10.1016/j.jacc.2021.09.021
Volume 78, Issue 21, 23 November 2021, Pages 2073-2075
Effectiveness of Implantable Cardioverter-Defibrillators to Reduce Mortality in Patients With Long QT Syndrome
MengWangPhDabDerick R.PetersonPhDcSpencerRoseroMDdScottMcNittMSaDavid Q.RichScDbefChristopher L.SeplakiPhDbgBronislavaPolonskyMSaIlanGoldenbergMDaWojciechZarebaMD, PhDa
doi : 10.1016/j.jacc.2021.09.017
Volume 78, Issue 21, 23 November 2021, Pages 2076-2088
The effectiveness of implantable cardioverter-defibrillators (ICDs) on reducing mortality has not been well studied in patients with long QT syndrome (LQTS).
The Quest for the Evidence of Effectiveness of Implantable Cardioverter-Defibrillators in Long QT Syndrome?
Manlio F.MárquezMD
doi : 10.1016/j.jacc.2021.09.020
Volume 78, Issue 21, 23 November 2021, Pages 2089-2091
Basic and Translational Research in Cardiac Repair and Regeneration: JACC State-of-the-Art Review
JianyiZhangMD, PhDaRobertoBolliMDbDaniel J.GarryMD, PhDcEduardoMarbánMD, PhDdPhilippeMenaschéMD, PhDeWolfram-HubertusZimmermannMDfTimothy J.KampMD, PhDgJoseph C.WuMD, PhDhVictor J.DzauMDi
doi : 10.1016/j.jacc.2021.09.019
Volume 78, Issue 21, 23 November 2021, Pages 2092-2105
This paper aims to provide an important update on the recent preclinical and clinical trials using cell therapy strategies and engineered heart tissues for the treatment of postinfarction left ventricular remodeling and heart failure. In addition to the authors’ own works and opinions on the roadblocks of the field, they discuss novel approaches for cardiac remuscularization via the activation of proliferative mechanisms in resident cardiomyocytes or direct reprogramming of somatic cells into cardiomyocytes. This paper’s main mindset is to present current and future strategies in light of their implications for the design of future patient trials with the ultimate objective of facilitating the translation of discoveries in regenerative myocardial therapies to the clinic.
Acute Aortic Syndrome Revisited: JACC State-of-the-Art Review
IsidreVilacostaMD, PhDaJ. AlbertoSan RománMD, PhDbcRobertodi BartolomeoMD, PhDdKimEagleMD, PhDeAnthony L.EstreraMD, PhDfgCarlosFerreraMD, PhDaShuichiroKajiMD, PhDhChristoph A.NienaberMD, PhDiVicençRiambauMD, PhDjHans-JoachimSchäfersMD, PhDkFrancisco J.SerranoMD, PhDaJae-KwanSongMD, PhDlLuisMarotoMD, PhDa
doi : 10.1016/j.jacc.2021.09.022
Volume 78, Issue 21, 23 November 2021, Pages 2106-2125
The purpose of this paper is to describe all available evidence on the distinctive features of a group of 4 life-threatening acute aortic pathologies gathered under the name of acute aortic syndrome (AAS). The epidemiology, diagnostic strategy, and management of these patients has been updated. The authors propose a new and simple diagnostic algorithm to support clinical decision making in cases of suspected AAS, thereby minimizing diagnostic delays, misdiagnoses, and unnecessary advanced imaging. AAS-related entities are reviewed, and a guideline to avoid imaging misinterpretation is provided. Centralization of patients with AAS in high-volume centers with high-volume surgeons is key to improving clinical outcomes. Thus, the role of multidisciplinary teams, an “aorta code” (streamlined emergent care pathway), and aortic centers in the management of these patients is boosted. A tailored patient treatment approach for each of these acute aortic entities is needed, and as such has been summarized. Finally, a set of prevention measures against AAS is discussed.
Increasing Prevalence of Critical Limb Ischemia Hospitalizations With Distinct Mental Health Burden Among Younger Adults
Kristie M.HarrisPhDCarlosMena-HurtadoMDAhmadArhamMDMatthew M.BurgPhDKenneth E.FreedlandPhDRajitaSinhaPhDOlamideAlabiMDKim G.SmolderenPhD
doi : 10.1016/j.jacc.2021.09.025
Volume 78, Issue 21, 23 November 2021, Pages 2126-2128
Triptans and SCAD: An Analysis From the WHO Pharmacovigilance Database
JustinePerezPharmDMarionLepelleyPharmDBrunoRevolPharmD, PhDMatthieuRoustitPharmD, PhDJean-LucCracowskiMD, PhDCharlesKhouriPharmD, PhD
doi : 10.1016/j.jacc.2021.09.024
Volume 78, Issue 21, 23 November 2021, Pages 2129-2130
